Wedbush Brokers Decrease Earnings Estimates for Scholar Rock

Scholar Rock Holding Co. (NASDAQ:SRRK) – Investment analysts at Wedbush dropped their Q2 2025 earnings per share (EPS) estimates for shares of Scholar Rock in a report issued on Wednesday, May 14th. Wedbush analyst D. Nierengarten now expects that the company will post earnings of ($0.66) per share for the quarter, down from their prior forecast of ($0.61). Wedbush currently has a “Outperform” rating and a $50.00 target price on the stock. The consensus estimate for Scholar Rock’s current full-year earnings is ($2.42) per share. Wedbush also issued estimates for Scholar Rock’s Q3 2025 earnings at ($0.64) EPS, Q4 2025 earnings at ($0.64) EPS, FY2025 earnings at ($2.61) EPS, Q1 2026 earnings at ($0.63) EPS, Q2 2026 earnings at ($0.58) EPS, Q3 2026 earnings at ($0.48) EPS, Q4 2026 earnings at ($0.36) EPS, FY2026 earnings at ($2.04) EPS, FY2027 earnings at ($0.58) EPS and FY2028 earnings at $0.49 EPS.

Scholar Rock (NASDAQ:SRRK) last issued its earnings results on Wednesday, May 14th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.63) by ($0.04). During the same period last year, the company earned ($0.59) EPS.

Scholar Rock Price Performance

Shares of NASDAQ SRRK opened at $31.54 on Monday. The firm has a market capitalization of $2.99 billion, a P/E ratio of -13.42 and a beta of 0.37. The firm’s 50-day moving average price is $31.01 and its 200-day moving average price is $35.94. The company has a current ratio of 3.88, a quick ratio of 3.88 and a debt-to-equity ratio of 0.63. Scholar Rock has a 1-year low of $6.76 and a 1-year high of $46.98.

Institutional Trading of Scholar Rock

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Global Retirement Partners LLC lifted its stake in shares of Scholar Rock by 584.7% in the fourth quarter. Global Retirement Partners LLC now owns 897 shares of the company’s stock valued at $39,000 after buying an additional 766 shares in the last quarter. CWM LLC increased its position in shares of Scholar Rock by 152.8% during the first quarter. CWM LLC now owns 996 shares of the company’s stock worth $32,000 after acquiring an additional 602 shares in the last quarter. Nisa Investment Advisors LLC raised its holdings in shares of Scholar Rock by 1,321.8% in the 4th quarter. Nisa Investment Advisors LLC now owns 1,109 shares of the company’s stock worth $48,000 after acquiring an additional 1,031 shares during the last quarter. GF Fund Management CO. LTD. bought a new position in Scholar Rock in the 4th quarter valued at about $85,000. Finally, Federated Hermes Inc. acquired a new position in Scholar Rock during the 1st quarter valued at about $71,000. Institutional investors own 91.08% of the company’s stock.

Insider Activity

In other news, Director Katie Peng sold 1,006 shares of the business’s stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $34.42, for a total transaction of $34,626.52. Following the completion of the sale, the director now owns 30,319 shares in the company, valued at $1,043,579.98. The trade was a 3.21% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CFO Edward H. Myles sold 142,292 shares of the stock in a transaction on Monday, March 10th. The stock was sold at an average price of $35.62, for a total value of $5,068,441.04. Following the completion of the transaction, the chief financial officer now owns 111,345 shares in the company, valued at approximately $3,966,108.90. This represents a 56.10% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 154,798 shares of company stock worth $5,482,238 in the last three months. Company insiders own 13.30% of the company’s stock.

About Scholar Rock

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.